Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ · Healthcare
Insight Molecular Diagnostics Inc. EBITDA 2020–2025
Insight Molecular Diagnostics Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Insight Molecular Diagnostics Inc. ebitda for the quarter ending March 31, 2026 was -3.8 M, a 40.04% decrease year-over-year.
- Insight Molecular Diagnostics Inc. ebitda for the twelve months ending March 31, 2026 was -29.8 M, a 8.26% decrease year-over-year.
- Insight Molecular Diagnostics Inc. annual ebitda for 2025 was -48.9 M, a 17.74% decrease from 2024.
- Insight Molecular Diagnostics Inc. annual ebitda for 2024 was -59.5 M, a 153.57% increase from 2023.
- Insight Molecular Diagnostics Inc. annual ebitda for 2023 was -23.5 M, a 42.43% increase from 2022.
- Insight Molecular Diagnostics Inc. annual ebitda for 2022 was -16.5 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Insight Molecular Diagnostics Inc. EBITDA — FAQ
Insight Molecular Diagnostics Inc. (IMDX) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IMDX's ebitda history?
The chart and table above show Insight Molecular Diagnostics Inc.'s ebitda by year and by quarter, including the growth rate.